-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Coinciding with International Women's Day on March 8, women's health issues have also received widespread attention in the industry
.
According to media reports, a hospital attaches great importance to women's health and rights, and designated March as the hospital's "Women's Health Care Month"
.
Around women's health issues, gynecological cancer is undoubtedly a big topic
.
Among them, ovarian cancer, one of the most common gynecological tumors in China, has more than 55,000 new cases every year
.
It is understood that clinically, about 70% of ovarian cancer patients are in the advanced stage when they are first diagnosed.
Although the remission rate of first-line treatment with surgery combined with platinum-containing chemotherapy can reach more than 80%, there are still 70% of ovarian cancer patients after the initial treatment.
Relapse within a year
.
In terms of survival time, 70% of patients are less than 7 years old
.
In general, the traditional treatment options for ovarian cancer are mainly surgery and chemotherapy, and most ovarian cancer patients need to receive second-line or even multi-line therapy
.
However, as the number of recurrences increases, the progression-free survival of patients will gradually shorten
.
Today, the treatment strategy for ovarian cancer has been transformed into a "surgery-chemotherapy-maintenance therapy" model
.
In recent years, with the advancement of medical technology and the improvement of clinical diagnosis and treatment of ovarian cancer, some new drugs and new programs have gradually been born, bringing new hope to patients
.
For example, first-line maintenance therapy of ovarian cancer targeted drug PARP inhibitors has become the standard treatment for ovarian cancer patients after complete or partial remission from first-line therapy, which can help patients better delay recurrence, reduce drug resistance, and prolong progression-free survival
.
However, the cost of PARP inhibitors, a targeted drug for ovarian cancer, has always been high, making many families of patients discouraged
.
In order to reduce the burden on patients, the National Medical Insurance Administration has also been working hard
.
In the past, Medicare reimbursed 15%-25% of patients with BRCA mutations who received maintenance therapy with PARP inhibitors, but not for newly diagnosed advanced ovarian cancer patients
.
In the new 2021 National Medical Insurance List, a total of 4 ovarian cancer targeted drugs are included, namely olaparib, niraparib, fluzoparib, and pamiparib.
.
Among the 4 drugs, except for olaparib, which maintained the original price, the other three have greatly reduced their prices
.
Among them, the imported drug niraparib has become more “close to the people”, whether patients with BRCA mutations or newly diagnosed advanced ovarian cancer patients can receive niraparib first-line maintenance treatment and enjoy medical insurance reimbursement
.
According to public information, the original price of the drug was 6,000 yuan/box (0.
1g*30 capsules), but it will be reduced to 4,584 yuan/box after entering medical insurance, a price reduction of 24%
.
Of course, the reimbursement rate of medical insurance will vary from region to region
.
It is reported that taking patients in Shanghai as an example, after reimbursement by medical insurance, the lower limit of the monthly personal payment of local patients in Shanghai is only less than 2,000 yuan, which will save more than 20,000 yuan compared to before medical insurance
.
The other two ovarian cancer targeted drugs, fluzoparib and pamiparib, are both domestically produced drugs, and the scope of reimbursement is for recurrent ovarian cancer
.
After entering the medical insurance, the price cuts of the two drugs reached 43% and 54% respectively
.
It is understood that the annual cost of these two drugs used to be more than 100,000 yuan.
After entering the medical insurance, the price has dropped by about half, and the average annual cost of patients will also be greatly reduced
.
From the country's move to include more good drugs and lower-priced drugs into medical insurance, it can be seen that the country's care for the majority of ovarian cancer patients has really brought good news to patients
.
With more patients using these drugs as soon as possible, it is expected to achieve long-term standardized treatment, and the survival period and quality of life will also be greatly improved
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
According to media reports, a hospital attaches great importance to women's health and rights, and designated March as the hospital's "Women's Health Care Month"
.
Around women's health issues, gynecological cancer is undoubtedly a big topic
.
Among them, ovarian cancer, one of the most common gynecological tumors in China, has more than 55,000 new cases every year
.
It is understood that clinically, about 70% of ovarian cancer patients are in the advanced stage when they are first diagnosed.
Although the remission rate of first-line treatment with surgery combined with platinum-containing chemotherapy can reach more than 80%, there are still 70% of ovarian cancer patients after the initial treatment.
Relapse within a year
.
In terms of survival time, 70% of patients are less than 7 years old
.
In general, the traditional treatment options for ovarian cancer are mainly surgery and chemotherapy, and most ovarian cancer patients need to receive second-line or even multi-line therapy
.
However, as the number of recurrences increases, the progression-free survival of patients will gradually shorten
.
Today, the treatment strategy for ovarian cancer has been transformed into a "surgery-chemotherapy-maintenance therapy" model
.
In recent years, with the advancement of medical technology and the improvement of clinical diagnosis and treatment of ovarian cancer, some new drugs and new programs have gradually been born, bringing new hope to patients
.
For example, first-line maintenance therapy of ovarian cancer targeted drug PARP inhibitors has become the standard treatment for ovarian cancer patients after complete or partial remission from first-line therapy, which can help patients better delay recurrence, reduce drug resistance, and prolong progression-free survival
.
However, the cost of PARP inhibitors, a targeted drug for ovarian cancer, has always been high, making many families of patients discouraged
.
In order to reduce the burden on patients, the National Medical Insurance Administration has also been working hard
.
In the past, Medicare reimbursed 15%-25% of patients with BRCA mutations who received maintenance therapy with PARP inhibitors, but not for newly diagnosed advanced ovarian cancer patients
.
In the new 2021 National Medical Insurance List, a total of 4 ovarian cancer targeted drugs are included, namely olaparib, niraparib, fluzoparib, and pamiparib.
.
Among the 4 drugs, except for olaparib, which maintained the original price, the other three have greatly reduced their prices
.
Among them, the imported drug niraparib has become more “close to the people”, whether patients with BRCA mutations or newly diagnosed advanced ovarian cancer patients can receive niraparib first-line maintenance treatment and enjoy medical insurance reimbursement
.
According to public information, the original price of the drug was 6,000 yuan/box (0.
1g*30 capsules), but it will be reduced to 4,584 yuan/box after entering medical insurance, a price reduction of 24%
.
Of course, the reimbursement rate of medical insurance will vary from region to region
.
It is reported that taking patients in Shanghai as an example, after reimbursement by medical insurance, the lower limit of the monthly personal payment of local patients in Shanghai is only less than 2,000 yuan, which will save more than 20,000 yuan compared to before medical insurance
.
The other two ovarian cancer targeted drugs, fluzoparib and pamiparib, are both domestically produced drugs, and the scope of reimbursement is for recurrent ovarian cancer
.
After entering the medical insurance, the price cuts of the two drugs reached 43% and 54% respectively
.
It is understood that the annual cost of these two drugs used to be more than 100,000 yuan.
After entering the medical insurance, the price has dropped by about half, and the average annual cost of patients will also be greatly reduced
.
From the country's move to include more good drugs and lower-priced drugs into medical insurance, it can be seen that the country's care for the majority of ovarian cancer patients has really brought good news to patients
.
With more patients using these drugs as soon as possible, it is expected to achieve long-term standardized treatment, and the survival period and quality of life will also be greatly improved
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
